Adriana Estrada‐Bernal

2.0k citations

30 papers · 1.1k indexed · 1 hit paper · h-index 16

Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 4
Oncology top 10%
- Lung Cancer Research Studies 3
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 13
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 3
- Cancer therapeutics and mechanisms 3
Pathology and Forensic Medicine top 10%
Cellular and Molecular Neuroscience
- Axon Guidance and Neuronal Signaling 4
Radiology, Nuclear Medicine and Imaging
- Radiopharmaceutical Chemistry and Applications 3
Cell Biology
- Microtubule and mitosis dynamics 3

Co-authors: Robert C. Doebele Anh T. Le Dara L. Aisner Karl H. Pfenninger Marileila Varella‐Garcia James R. Van Brocklyn Andrea E. Doak Brian B. Tuch
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Nucleic Acids Research (1 paper)PLoS ONE (2 papers)Cancer Research (4 papers)
Partner nations: United States New Zealand Mexico

In The Last Decade

Adriana Estrada‐Bernal

30 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Adriana Estrada‐Bernal

Since Specialization

Citations

This map shows the geographic impact of Adriana Estrada‐Bernal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adriana Estrada‐Bernal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adriana Estrada‐Bernal more than expected).

Fields of papers citing papers by Adriana Estrada‐Bernal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adriana Estrada‐Bernal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adriana Estrada‐Bernal. The network helps show where Adriana Estrada‐Bernal may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Adriana Estrada‐Bernal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Adriana Estrada‐Bernal Line = papers co-authored together Adriana Estrada‐Bernal links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ERBB family fusions are recurrent and actionable oncogenic targets across cancer types Frontiers in Oncology ·Laura Schubert,Andrew Elliott,Anh T. Le,Adriana Estrada‐Bernal,Robert C. Doebele,Emil Lou,Hossein Borghaei,Michael J. Demeure,Razelle Kurzrock,Joshua E. Reuss,Sai‐Hong Ignatius Ou,David R. Braxton,Christian A. Thomas,Sourat Darabi,W. Michael Korn,Wafik S. El‐Deiry,Stephen V. Liu	2023	8
2	Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling Molecular Pharmacology ·Laura Schubert,Anh T. Le,Adriana Estrada‐Bernal,Andrea E. Doak,Minjae Yoo,Sarah E. Ferrara,Andrew Goodspeed,Fumi Kinose,Uwe Rix,Aik Choon Tan,Robert C. Doebele	2021	6
3	Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair Nucleic Acids Research ·Linlin Yang,Changxian Shen,Adriana Estrada‐Bernal,Ryan Robb,Moumita Chatterjee,Nikhil Sebastian,Amy Webb,Xiaokui Mo,Wei Chen,Sunil Krishnan,Terence M. Williams	2021	48
4	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes Clinical Cancer Research ·Adriana Estrada‐Bernal,Anh T. Le,Andrea E. Doak,Vijaya G. Tirunagaru,Shevan Silva,Matthew R. Bull,Jeff B. Smaill,Adam V. Patterson,Chul Kim,Stephen V. Liu,Robert C. Doebele	2020	71
5	Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer Clinical Cancer Research ·Caroline E. McCoach,Anh T. Le,Katherine Gowan,Kenneth A. Jones,Laura Schubert,Andrea E. Doak,Adriana Estrada‐Bernal,Kurtis D. Davies,Daniel T. Merrick,Paul A. Bunn,W. Tom Purcell,Rafał Dziadziuszko,Marileila Varella‐Garcia,Dara L. Aisner,D. Ross Camidge,Robert C. Doebele	2018	179
6	Abstract A29: The CUTO panel of patient-derived NSCLC cell lines reveals unique molecular characteristics and responses to targeted therapies Clinical Cancer Research ·Anh T. Le,Adriana Estrada‐Bernal,Laura Schubert,Andrea E. Doak,Nan Chen,Kurtis D. Davies,Aria Vaishnavi,Mary Jackson,Vignesh Narayana,Kimi Kondo,John D. Mitchell,Michael J. Weyant,Tom Purcell,Paul A. Bunn,D. Ross Camidge,Janet Freeman-Daly,Robert C. Doebele	2018	2
7	Abstract A157: Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions Molecular Cancer Therapeutics ·Adriana Estrada‐Bernal,Andrea E. Doak,Anh T. Le,Hengbo Zhu,Nan Chen,Shevan Silva,Jeff B. Smaill,Adam V. Patterson,Robert C. Doebele	2018	16
8	An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101breakdown → Cancer Discovery ·Robert C. Doebele,Lara E. Davis,Aria Vaishnavi,Anh T. Le,Adriana Estrada‐Bernal,Stephen B. Keysar,Antonio Jimeno,Marileila Varella‐Garcia,Dara L. Aisner,Yali Li,Philip J. Stephens,Deborah Morosini,Brian B. Tuch,Michele Fernandes,Nisha Nanda,Jennifer A. Low	2015	302
9	Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions Molecular Cancer Therapeutics ·David S. Hong,Marcia S. Brose,Robert C. Doebele,Alice T. Shaw,Afshin Dowlati,Todd M. Bauer,Anna F. Farago,Adriana Estrada‐Bernal,Anh T. Lee,Michael C. Cox,Nisha Nanda,Jennifer A. Low,Howard A. Burris	2015	12
10	MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways Cell Cycle ·Adriana Estrada‐Bernal,Moumita Chatterjee,S. Jaharul Haque,Linlin Yang,Meredith A. Morgan,Shweta Kotian,David J. Morrell,Arnab Chakravarti,Terence M. Williams	2015	52
11	Amyloid Precursor Protein Is an Autonomous Growth Cone Adhesion Molecule Engaged in Contact Guidance PLoS ONE ·Lucas J. Sosa,Jared Bergman,Adriana Estrada‐Bernal,Thomas J. Glorioso,John M. Kittelson,Karl H. Pfenninger	2013	36
12	Dosage of amyloid precursor protein affects axonal contact guidance in Down syndrome The FASEB Journal ·Lucas J. Sosa,Nienke L. Postma,Adriana Estrada‐Bernal,Michael G. Hanna,Ruifang Guo,Jorge Busciglio,Karl H. Pfenninger	2013	16
13	Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma Neuro-Oncology ·Adriana Estrada‐Bernal,Kamalakannan Palanichamy,A. Ray Chaudhury,James R. Van Brocklyn	2012	73
14	Functional Complexity of the Axonal Growth Cone: A Proteomic Analysis PLoS ONE ·Adriana Estrada‐Bernal,Staci D. Sanford,Lucas J. Sosa,Glenn C. Simon,Kirk C. Hansen,Karl H. Pfenninger	2012	37
15	The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells Journal of Neuro-Oncology ·Adriana Estrada‐Bernal,Sean Lawler,Michal O. Nowicki,Abhik Ray Chaudhury,James R. Van Brocklyn	2010	28
16	Dynamic adhesions and MARCKS in melanoma cells Journal of Cell Science ·Adriana Estrada‐Bernal,Jesse C. Gatlin,Somkiat Sunpaweravong,Karl H. Pfenninger	2009	29
17	Kv1 Potassium Channel Complexes In Vivo Require Kvβ2 Subunits in Dorsal Spinal Neurons Journal of Neurophysiology ·Ricardo H. Pineda,Christopher S. Knoeckel,Alison D. Taylor,Adriana Estrada‐Bernal,Angeles B. Ribera	2008	8
18	Myristoylated, Alanine-rich C-Kinase Substrate Phosphorylation Regulates Growth Cone Adhesion and Pathfinding Molecular Biology of the Cell ·Jesse C. Gatlin,Adriana Estrada‐Bernal,Staci D. Sanford,Karl H. Pfenninger	2006	51
19	The inhibitor protein of the F1F0-ATP synthase is associated to the external surface of endothelial cells Biochemical and Biophysical Research Communications ·Paulina Cortés-Hernández,Lenin Domínguez‐Ramírez,Adriana Estrada‐Bernal,Delina Montés-Sánchez,Alejandro Zentella‐Dehesa,Marietta Tuena de Gómez‐Puyou,Armando Gómez‐Puyou,Joaquín J. García	2005	30
20	NF-κB dependent activation of human endothelial cells treated with soluble products derived from human lymphomas Cancer Letters ·Adriana Estrada‐Bernal,Criselda Mendoza-Milla,José Luis Ventura-Gallegos,Lucia Nikolaia López-Bojórquez,Enrique Miranda-Peralta,Fabián Arechavaleta-Velasco,Felipe Vadillo‐Ortega,Luis Sánchez‐Sánchez,Alejandro Zentella‐Dehesa	2003	12

About Adriana Estrada‐Bernal

Adriana Estrada‐Bernal is a scholar working on Cancer Research, Cell Biology and Pulmonary and Respiratory Medicine, having authored 30 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Cancer, Hypoxia, and Metabolism (4 papers), Axon Guidance and Neuronal Signaling (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Microtubule and mitosis dynamics (3 papers), Lung Cancer Research Studies (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Cancer therapeutics and mechanisms (3 papers). The work is most often cited by research in Cancer Research (244 citations), Oncology (439 citations) and Pulmonary and Respiratory Medicine (467 citations). Adriana Estrada‐Bernal has collaborated with scholars based in United States, New Zealand and Mexico. Frequent co-authors include Robert C. Doebele, Anh T. Le, Dara L. Aisner, Karl H. Pfenninger, Marileila Varella‐Garcia, James R. Van Brocklyn, Andrea E. Doak, Brian B. Tuch, Jennifer A. Low and Jesse C. Gatlin. Their work appears in journals such as Nucleic Acids Research, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact